Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment.
Linqmed has raised $2.0M in total funding. The most recent round was Series B. The last funding was announced in May 2025.
Linqmed's investors include Mitsubishi UFJ Capital, Mizuho Capital, Nissay Capital, JIC Venture Growth Investments, Keio Innovation Initiative.
Linqmed is headquartered in Chiba, Japan.
Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment.
Linqmed is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Linqmed — Funding & Investors." VCBacked, May 12, 2025, https://www.vcbacked.co/company/linqmed. Accessed August 14, 2026.
VCBacked. (2025). Linqmed — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/linqmed
{{cite web |title=Linqmed — Funding & Investors |url=https://www.vcbacked.co/company/linqmed |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated